GPI Presented Research
Featured Research
Regulatory and reimbursement landscape for Cell and Gene Therapies across Europe
By Danni Dale |
- All
- 2024
- 2023
- 2022
- 2021
USA pricing data
Background The fragmented payer system in the USA presents challenges to understanding pricing for market access and pricing decisions. We know that access to prices beyond just Wholesale Acquisition Cost (WAC) are important to understand drug expenditure and pricing across payer types. At GPI, we provide one place for 6 different price types for the…
Explore the pinnacle of our contributions at ISPOR 2023 Our team presented five cutting-edge research posters that redefine the landscape of healthcare economics and market access. Each poster encapsulates a wealth of insights, innovations, and strategic perspectives crafted by our expert team at GPI. Our posters delve into key themes shaping the future of market…
Importance of time horizon and analogue selection for value-based pricing of cell and gene therapies
AUTHOR(S) Anstee K, Jao R
Regulatory and reimbursement landscape for Cell and Gene Therapies across Europe
AUTHOR(S)
Beards E, Song X, Kodabuckus S
Solving the Chinese puzzle: What determines reimbursement price in China?
AUTHOR(S)
Song X, Kodabuckus S, Patel P
The relationship between value and price in the free-pricing period and post-assessment price in Germany, a case study in rheumatoid arthritis
AUTHOR(S)
Cigerli S, Anstee K, Patel P
Suitability of value-based price forecasting in a crowded landscape: A case study in rheumatoid arthritis
AUTHOR(S)
Anstee K, Patel P
The National Pricing & Reimbursement Process in China, a 2021 update
The research looks into detail at The Chinese National Reimbursement Drug List (NRDL) and reforms that have resulted in changes to the reimbursement process and how new drugs are launched within the market.
List prices for Medicare negotiation-eligible medicines targeted by Build Back Better
GPI attended ISPOR last month, in Washington D.C, and had the opportunity to present three research abstracts, including “List prices for Medicare negotiation-eligible medicines targeted by Build Back Better drug pricing provisions estimated to be reduced by over 40% on average.”
Value Assessment & Price Forecasting
Find out more about value assessment and price forecasting, and how GPI can optimise your pricing strategy with our award winning methodology GPI horizon
Find out more
Engage with us
Register your interest
in GPI solutions
Sign up for
GPI updates